Senologie - Zeitschrift für Mammadiagnostik und -therapie 2015; 12 - A9
DOI: 10.1055/s-0035-1550450

SPARC expression in primary metastatic breast cancer

J Barinoff 1, C Brandi 2, M Thill 3, C Heinrichs 4, J Mensah 5, W Weikel 6, A Fisseler-Eckhoff 7, H Sinn 8, A Meyer 9, A Traut 10, A Schneeweiss 11
  • 1Agaplesion Markus Krankenhaus Frankfurt am Main, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Deutschland
  • 2Wilhelm-Epstein-Str. 4, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Deutschland
  • 3Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Deutschland
  • 4Gemeinschaftspraxis Für Pathologie, Frankfurt am Main, Deutschland
  • 5Kliniken Essen Mitte, Klinik für Senologie, Essen, Deutschland
  • 6Dr.-Horst-Schmidt-Klinik, Klinik für Gynäkologie und Gynäkologische Onkologie, Wiesbaden, Deutschland
  • 7Hsk Kliniken Wiesbaden, Institut F. Pathologie U. Zytologie (Ipz), Wiesbaden, Deutschland
  • 8Klinikum Heidelberg, Institut für Pathologie Sektion Gynäkopathologie, Heidelberg, Deutschland
  • 9Uniklinik Heilderberg, Heidelberg, Deutschland
  • 10Kliniken Essen Mitte, Essen, Deutschland
  • 11Universitätsklinikum Heidelberg, Frauenklinik/Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland

Einleitung/Zielsetzung:

To evaluate the prognostic value of the expression of secreted protein acidic and rich in cysteine (SPARC) in primary metastatic breast cancer (PMBC).

Material & Methoden:

Fifty-two patients with PMBC diagnosed between 2005 and 2012 at x German centers were retrospectively analyzed for expression of SPARC in tumor cells using an immunoreactive score (IRS) integrating staining intensity and percentage of positive cells (IRS 0 – 12), and in stroma based on immunohistochemical (IHC) staining intensity only (IHC 0 – 3+). Association between SPARC expression, tumor characteristics and progression-free survival (PFS) and overall survival (OS) was analyzed.

Ergebnisse:

Only Her2 expression was associated with expression of SPARC in stroma (p 0.028, OR 13.9 95% 1.3 – 145.5) but not in tumor cells. SPARC expression in stroma was associated with shorter PFS (hazard ratio (HR) 2.6; 95% confidence interval (CI) 1.2 – 5.4; p 0.014), but not in tumor cells (fig.1) and shorter OS (HR 4.1; 95% CI 1.04 – 16; p 0.041) for SPARC expression in stroma of breast tumor (fig. 2). No clear association between expression of SPARC in tumor cells and outcome could be detected.

Zusammenfassung:

Only SPARC expression in stroma might be associated with shorter PFS and OS in patients with PMBC. This finding is in line with the known key role of expression of SPARC in the metastastatic process. Confirmation in prospective clinical trials is warranted.